160 related articles for article (PubMed ID: 37279651)
21. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN
J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762
[TBL] [Abstract][Full Text] [Related]
22. Optimizing glioblastoma temozolomide chemotherapy employing lentiviral-based anti-MGMT shRNA technology.
Viel T; Monfared P; Schelhaas S; Fricke IB; Kuhlmann MT; Fraefel C; Jacobs AH
Mol Ther; 2013 Mar; 21(3):570-9. PubMed ID: 23319055
[TBL] [Abstract][Full Text] [Related]
23. Cedrol, a Sesquiterpene Alcohol, Enhances the Anticancer Efficacy of Temozolomide in Attenuating Drug Resistance via Regulation of the DNA Damage Response and MGMT Expression.
Chang KF; Huang XF; Chang JT; Huang YC; Lo WS; Hsiao CY; Tsai NM
J Nat Prod; 2020 Oct; 83(10):3021-3029. PubMed ID: 32960603
[TBL] [Abstract][Full Text] [Related]
24. SNAP reverses temozolomide resistance in human glioblastoma multiforme cells through down-regulation of MGMT.
Tsai CK; Huang LC; Wu YP; Kan IY; Hueng DY
FASEB J; 2019 Dec; 33(12):14171-14184. PubMed ID: 31725331
[TBL] [Abstract][Full Text] [Related]
25. Glioblastoma Recurrence and the Role of O
Storey K; Leder K; Hawkins-Daarud A; Swanson K; Ahmed AU; Rockne RC; Foo J
JCO Clin Cancer Inform; 2019 Feb; 3():1-12. PubMed ID: 30758983
[TBL] [Abstract][Full Text] [Related]
26. Resveratrol Enhances Temozolomide Efficacy in Glioblastoma Cells through Downregulated MGMT and Negative Regulators-Related STAT3 Inactivation.
Wu M; Song D; Li H; Ahmad N; Xu H; Yang X; Wang Q; Cheng X; Deng S; Shu X
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298405
[TBL] [Abstract][Full Text] [Related]
27. Temozolomide Induces the Acquisition of Invasive Phenotype by O6-Methylguanine-DNA Methyltransferase (MGMT)
Kochanowski P; Catapano J; Pudełek M; Wróbel T; Madeja Z; Ryszawy D; Czyż J
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923767
[TBL] [Abstract][Full Text] [Related]
28. USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization.
Liu J; Wang K; Zhu Q; Zhang Y; Chen Y; Lou Z; Yuan J
CNS Neurosci Ther; 2024 Apr; 30(4):e14711. PubMed ID: 38644551
[TBL] [Abstract][Full Text] [Related]
29. LncRNA UCA1/miR-182-5p/MGMT axis modulates glioma cell sensitivity to temozolomide through MGMT-related DNA damage pathways.
Cheng M; Wang Q; Chen L; Zhao D; Tang J; Xu J; He Z
Hum Pathol; 2022 May; 123():59-73. PubMed ID: 35219686
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
31. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
Kitange GJ; Carlson BL; Schroeder MA; Grogan PT; Lamont JD; Decker PA; Wu W; James CD; Sarkaria JN
Neuro Oncol; 2009 Jun; 11(3):281-91. PubMed ID: 18952979
[TBL] [Abstract][Full Text] [Related]
32. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
[TBL] [Abstract][Full Text] [Related]
33. BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression.
Tancredi A; Gusyatiner O; Bady P; Buri MC; Lomazzi R; Chiesi D; Messerer M; Hegi ME
Cell Death Dis; 2022 Dec; 13(12):1037. PubMed ID: 36513631
[TBL] [Abstract][Full Text] [Related]
34. Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
Hu YH; Jiao BH; Wang CY; Wu JL
CNS Neurosci Ther; 2021 May; 27(5):552-563. PubMed ID: 33460245
[TBL] [Abstract][Full Text] [Related]
35. Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide.
van Nifterik KA; van den Berg J; van der Meide WF; Ameziane N; Wedekind LE; Steenbergen RD; Leenstra S; Lafleur MV; Slotman BJ; Stalpers LJ; Sminia P
Br J Cancer; 2010 Jun; 103(1):29-35. PubMed ID: 20517307
[TBL] [Abstract][Full Text] [Related]
36. mTOR inhibition and levels of the DNA repair protein MGMT in T98G glioblastoma cells.
Smalley S; Chalmers AJ; Morley SJ
Mol Cancer; 2014 Jun; 13():144. PubMed ID: 24909675
[TBL] [Abstract][Full Text] [Related]
37. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
38. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.
Wang HH; Chang TY; Lin WC; Wei KC; Shin JW
Sci Rep; 2017 Aug; 7(1):8814. PubMed ID: 28821714
[TBL] [Abstract][Full Text] [Related]
39. EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma.
Struve N; Binder ZA; Stead LF; Brend T; Bagley SJ; Faulkner C; Ott L; Müller-Goebel J; Weik AS; Hoffer K; Krug L; Rieckmann T; Bußmann L; Henze M; Morrissette JJD; Kurian KM; Schüller U; Petersen C; Rothkamm K; O Rourke DM; Short SC; Kriegs M
Oncogene; 2020 Apr; 39(15):3041-3055. PubMed ID: 32066879
[TBL] [Abstract][Full Text] [Related]
40. Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines.
Fishman H; Monin R; Dor-On E; Kinzel A; Haber A; Giladi M; Weinberg U; Palti Y
J Neurooncol; 2023 May; 163(1):83-94. PubMed ID: 37131108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
